This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Zimmer Biotech Gmbh. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Andre Solioz: Innovator in Pharmaceutical Solutions
Introduction
Andre Solioz is a notable inventor based in Basel, Switzerland. She has made significant contributions to the field of pharmaceuticals, particularly in the development of topical delivery systems. Her innovative work focuses on enhancing the effectiveness of treatments through advanced formulations.
Latest Patents
One of her key patents is for a hydrophilic gel designed for the topical delivery of 5-aminolevulinic acid (5-ALA). This invention relates to a pharmaceutical topical gel solution that contains 5-ALA and an aqueous low viscous gel matrix. The formulation can be utilized in photodynamic therapy as well as in the photodynamic detection of abnormally proliferating cells. This patent highlights her commitment to improving therapeutic options in medicine.
Career Highlights
Andre Solioz is associated with Zimmer Biotech GmbH, where she continues to innovate in the pharmaceutical sector. Her work is characterized by a focus on practical applications that can significantly impact patient care and treatment outcomes.
Collaborations
She collaborates with esteemed colleagues such as Frank Stowasser and Armin Zimmer, contributing to a dynamic research environment that fosters innovation and development.
Conclusion
Andre Solioz stands out as a pioneering inventor in the pharmaceutical industry, with her work on topical delivery systems showcasing her dedication to advancing medical treatments. Her contributions are vital in the ongoing quest for effective therapeutic solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile